FCH
RVNC

Freestone Capital Holdings’s Revance Therapeutics, Inc. RVNC Stock Holding History

Freestone Capital Holdings’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-18,020
Closed -$93.5K – 477
2024
Q3 		$93.5K Buy
+18,020
New +$89.6K ﹤0.01% 424
2024
Q2 		– Sell
-18,020
Closed -$88.7K – 486
2024
Q1 		$88.7K Hold
18,020
– – ﹤0.01% 429
2023
Q4 		$158K Hold
18,020
– – 0.01% 381
2023
Q3 		$207K Hold
18,020
– – 0.01% 339
2023
Q2 		$456K Hold
18,020
– – 0.02% 263
2023
Q1 		$580K Hold
18,020
– – 0.03% 239
2022
Q4 		$333K Sell
18,020
-12,236
-40% -$280K 0.02% 283
2022
Q3 		$817K Hold
30,256
– – 0.04% 215
2022
Q2 		$418K Buy
30,256
+599
+2% +$9.22K 0.02% 285
2022
Q1 		$578K Hold
29,657
– – 0.02% 319
2021
Q4 		$484K Buy
29,657
+383
+1% +$6.38K 0.02% 322
2021
Q3 		$816K Hold
29,274
– – 0.04% 234
2021
Q2 		$868K Hold
29,274
– – 0.04% 225
2021
Q1 		$818K Hold
29,274
– – 0.04% 223
2020
Q4 		$830K Buy
+29,274
New +$758K 0.05% 205

Other funds holding RVNC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Freestone Capital Holdings's RVNC Position: Q4 2024 in Review

Freestone Capital Holdings sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2024, closing a stake of 18,020 shares — an estimated $93.5K sold.

Freestone Capital Holdings first reported a position in RVNC in Q4 2020 and held it in 15 quarters. The position peaked at $868K in Q2 2021. 173 funds tracked by Wall St. Rank hold RVNC as of Q4 2024.

  • Freestone Capital Holdings reported no remaining Revance Therapeutics, Inc. position as of Q4 2024 after selling out during the quarter.
  • Freestone Capital Holdings sold 18,020 Revance Therapeutics, Inc. shares in Q4 2024, an estimated $93.5K.
  • Freestone Capital Holdings first reported a position in Revance Therapeutics, Inc. in Q4 2020 and held it in 15 quarters.
  • Freestone Capital Holdings's Revance Therapeutics, Inc. position peaked at $868K in Q2 2021.
  • 173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2024.

Based on Freestone Capital Holdings's 13F filing for Q4 2024, filed 6 Feb 2025.